Clinical Trial Update: A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating STM-416 in patients undergoing TURBT for recurrent non-muscle-invasive bladder cancer; recruitment is currently ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• STM-416

Snippet

Sponsor: SURGE Therapeutics | Conditions: Non-muscle-invasive Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING